CONCLUSION: Opioid dependency, whether it results from the misuse or abuse of prescription or street drugs, continues to be a significant public health issue. Passage of DATA 2000 and US Food and Drug Administration approval of buprenorphine and buprenorphine/ naloxone has revolutionized opioid dependence therapy. The traditional addiction medicine therapy regimen of methadone maintenance, with […]

CONCLUSIONS: Prompt attention to those with early non-adherence to medication or an early opioid positive urine, markers available in the first 2weeks of treatment, may improve treatment retention. Extended Bup/Nal treatment appeared effective in improving treatment retention for youth with opioid dependence across a wide range of demographics, and pre-treatment clinical characteristics. PMID: 22626890 [PubMed […]

Authors: Westermeyer J, McCance-Katz EF Abstract Currently published information on buprenorphinenaloxone withdrawal recommends a gradually decreasing dosage over weeks to months. In this case report, abrupt cessation of buprenorphine/naloxone at various doses, and after variable durations of treatment, resulted in mild opiate withdrawal lasting over approximately 1-2 days that did not require additional opioid medication […]

RICHMOND, Va., Aug. 20, 2012 (HSMN NewsFeed) — Reckitt Benckiser Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration (FDA) approval of the 4 mg and 12 mg doses of Suboxone® (buprenorphine and naloxone) sublingual film. Suboxon… Biopharmaceuticals, FDAReckitt Benckiser, Suboxone, buprenorphine, naloxone (Source: HSMN NewsFeed)